Published in Prog Clin Biol Res on January 01, 1980
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A (2004) 3.68
Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach. BMC Genomics (2006) 2.98
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet (2002) 2.24
Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun (2016) 2.22
PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate (2011) 2.13
Early contribution of pericytes to angiogenic sprouting and tube formation. Angiogenesis (2003) 1.89
The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res (2009) 1.88
Ligand-dependent enhancer activation regulated by topoisomerase-I activity. Cell (2015) 1.74
Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer (2005) 1.73
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One (2012) 1.63
Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia (2005) 1.63
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer (2015) 1.55
3D Cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayer. PLoS One (2014) 1.54
Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169. Invest New Drugs (2003) 1.49
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst (2007) 1.41
Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci U S A (2002) 1.40
Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci U S A (2009) 1.37
Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reprod Biol Endocrinol (2004) 1.29
Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A (1992) 1.28
ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia (2012) 1.28
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries. BMC Genomics (2009) 1.24
"True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer. J Med Chem (2012) 1.19
Steroid hormone induction and expression patterns of L-plastin in normal and carcinomatous prostate tissues. Am J Pathol (1997) 1.18
Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis (2013) 1.17
Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects. PLoS One (2008) 1.13
Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. PLoS One (2013) 1.11
Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia (2005) 1.11
Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J Virol (2002) 1.10
Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc. Cancer Sci (2011) 1.10
The non-phagocytic route of collagen uptake: a distinct degradation pathway. J Biol Chem (2011) 1.09
Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate (2009) 1.08
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest (1993) 1.08
Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer (2010) 1.08
Cadmium--a metallohormone? Toxicol Appl Pharmacol (2009) 1.07
The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol (2002) 1.06
Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat Rev (2013) 1.05
Dentatin Induces Apoptosis in Prostate Cancer Cells via Bcl-2, Bcl-xL, Survivin Downregulation, Caspase-9, -3/7 Activation, and NF-κB Inhibition. Evid Based Complement Alternat Med (2012) 1.04
ADAM-mediated amphiregulin shedding and EGFR transactivation. Cell Prolif (2009) 1.03
Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci (2011) 1.03
Consumption of oxygen: a mitochondrial-generated progression signal of advanced cancer. Cell Death Dis (2012) 1.02
Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis. Neoplasia (2001) 1.02
The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol (2012) 1.01
Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia (2005) 0.99
A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol (2002) 0.97
Endocytic uptake of a large array of HPMA copolymers: Elucidation into the dependence on the physicochemical characteristics. J Control Release (2010) 0.97
Detecting gene-gene interactions in prostate disease in African American men. Infect Agent Cancer (2011) 0.97
Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer. Oncotarget (2015) 0.93
Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol (2010) 0.92
Anti-neoplastic activity of two flavone isomers derived from Gnaphalium elegans and Achyrocline bogotensis. PLoS One (2012) 0.92
Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Mol Ther (2010) 0.91
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget (2015) 0.90
The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian J Androl (2008) 0.90
Cadmium induces p53-dependent apoptosis in human prostate epithelial cells. PLoS One (2012) 0.90
Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget (2015) 0.90
Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res (2009) 0.90
Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PLoS One (2014) 0.88
Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon. Biochim Biophys Acta (2011) 0.87
Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP. Br J Cancer (1991) 0.87
Overexpression of α (1,6) fucosyltransferase associated with aggressive prostate cancer. Glycobiology (2014) 0.87
MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. Br J Cancer (2008) 0.86
Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl (2014) 0.86
The aryl hydrocarbon receptor is constitutively active in advanced prostate cancer cells. PLoS One (2014) 0.85
LHRH-conjugated lytic peptides directly target prostate cancer cells. Biochem Pharmacol (2010) 0.85
Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs (2002) 0.84
Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells. PLoS One (2013) 0.83
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines. PLoS One (2014) 0.83
Suppression of AKT anti-apoptotic signaling by a novel drug candidate results in growth arrest and apoptosis of hepatocellular carcinoma cells. PLoS One (2013) 0.83
Elevated expression of L-selectin ligand in lymph node-derived human prostate cancer cells correlates with increased tumorigenicity. Glycoconj J (2008) 0.83
Dual activation of pathways regulated by steroid receptors and peptide growth factors in primary prostate cancer revealed by Factor Analysis of microarray data. BMC Genomics (2005) 0.83
p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines. Prostate (2013) 0.83
Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemother Pharmacol (2010) 0.82
Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations. Am J Pathol (1999) 0.81
Transcriptional down-regulation of c-myc in human prostate carcinoma cells by the synthetic androgen mibolerone. Br J Cancer (1992) 0.81
Tyrosyl kinase activity is inversely related to prostatic acid phosphatase activity in two human prostate carcinoma cell lines. Mol Cell Biol (1986) 0.81
XMRV induces cell migration, cytokine expression and tumor angiogenesis: are 22Rv1 cells a suitable prostate cancer model? PLoS One (2012) 0.81
In vitro and in vivo model systems used in prostate cancer research. J Biol Methods (2015) 0.81
The anti-proliferative effects of enterolactone in prostate cancer cells: evidence for the role of DNA licencing genes, mi-R106b cluster expression, and PTEN dosage. Nutrients (2014) 0.81
Effects of triclocarban on intact immature male rat: augmentation of androgen action. Reprod Sci (2010) 0.81
Activin receptor signaling regulates prostatic epithelial cell adhesion and viability. Neoplasia (2009) 0.81
DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. Mol Cancer (2014) 0.81
Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling. Int J Mol Sci (2013) 0.80
Evaluating baculovirus as a vector for human prostate cancer gene therapy. PLoS One (2013) 0.80
The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study. PLoS One (2016) 0.79
Hemostatic gelatin sponge is a superior matrix to matrigel for establishment of LNCaP human prostate cancer in nude mice. Prostate (2012) 0.79
Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer. Br J Cancer (2009) 0.79
Hyaluronan in aged collagen matrix increases prostate epithelial cell proliferation. In Vitro Cell Dev Biol Anim (2014) 0.79
Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation. Endocrinology (2013) 0.79
The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells. Mol Cancer (2014) 0.79
ERBB2 increases metastatic potentials specifically in androgen-insensitive prostate cancer cells. PLoS One (2014) 0.79
Mouse models for studying prostate cancer bone metastasis. Bonekey Rep (2016) 0.78
Identification of beta-2 as a key cell adhesion molecule in PCa cell neurotropic behavior: a novel ex vivo and biophysical approach. PLoS One (2014) 0.78
Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol Cancer (2010) 0.78
FUS/TLS is a co-activator of androgen receptor in prostate cancer cells. PLoS One (2011) 0.78
CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. Horm Cancer (2016) 0.78
Isolation and analysis of discreet human prostate cellular populations. Differentiation (2015) 0.77
20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer. PLoS One (2014) 0.77
Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells. Am J Transl Res (2010) 0.76
Methylselenocysteine preventing castration-resistant progression of prostate cancer. Prostate (2015) 0.75
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science (1985) 12.75
Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science (1984) 10.40
LNCaP model of human prostatic carcinoma. Cancer Res (1983) 7.23
Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A (1984) 4.90
Sarcoidosis of the Spleen: Report of a Case with Autopsy and a Study of Intracellular "Asteroid Bodies". Am J Pathol (1944) 4.55
Differential expression of the amv gene in human hematopoietic cells. Proc Natl Acad Sci U S A (1982) 4.37
Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature (1984) 4.35
AMEE Guide No. 14: Outcome-based education: Part 5-From competency to meta-competency: a model for the specification of learning outcomes. Med Teach (1999) 4.30
Macromolecule synthesis and breakdown in relation to sporulation and meiosis in yeast. J Bacteriol (1974) 4.07
Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med (1993) 3.37
Purification of a human prostate specific antigen. Invest Urol (1979) 3.11
Coronary heart disease in Western Collaborative Group Study. Final follow-up experience of 8 1/2 years. JAMA (1975) 2.84
Gardner syndrome in a man with an interstitial deletion of 5q. Am J Med Genet (1986) 2.78
The chromatographic determination of cystine and cysteine residues in proteins as s-beta-(4-pyridylethyl)cysteine. J Biol Chem (1970) 2.59
Carcinoembryonic antigen in patients with different cancers. JAMA (1972) 2.56
Threshold adrenocortical sensitivity in man and its possible application to corticotrophin bioassay. Lancet (1967) 2.44
Pharmacoeconomic evaluation of COPD. Chest (2000) 2.35
Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to the findings of the Framingham study. Circulation (1976) 2.35
Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med (1995) 2.29
Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA. J Immunol (1984) 2.27
The journal "impact factor": a misnamed, misleading, misused measure. Cancer Genet Cytogenet (1998) 2.23
Hemangioendothelial sarcoma of liver from chronic arsenic intoxication by Fowler's solution. Cancer (1968) 2.22
Substrate specificity of the dsRNA unwinding/modifying activity. EMBO J (1991) 2.18
Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 2.16
Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. J Natl Cancer Inst (1992) 2.16
A framework for developing excellence as a clinical educator. Med Educ (2001) 2.14
Human T-cell growth factor: partial amino acid sequence, cDNA cloning, and organization and expression in normal and leukemic cells. Proc Natl Acad Sci U S A (1984) 2.12
CT of small-bowel obstruction: value in establishing the diagnosis and determining the degree and cause. AJR Am J Roentgenol (1994) 2.05
Polymorphism of the 3' open reading frame of the virus associated with the acquired immune deficiency syndrome, human T-lymphotropic virus type III. Nucleic Acids Res (1985) 2.01
Cushing's syndrome: diagnostic criteria. Q J Med (1966) 2.00
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer (1999) 1.99
Culture of human leukemia cells. Cancer (1966) 1.94
New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. Nature (1987) 1.93
Carcinoembryonic antigen (CEA) as a prognostic and monitoring test in clinically complete resection of colorectal carcinoma. Ann Surg (1976) 1.92
Disappearance of a structural chromatin protein A24 in mitosis: implications for molecular basis of chromatin condensation. Proc Natl Acad Sci U S A (1979) 1.91
First-pass ventricular ejection fraction using a single-crystal nuclear camera. J Nucl Med (1994) 1.91
Synthesis of the complete trans-activation gene product of human T-lymphotropic virus type III in Escherichia coli: demonstration of immunogenicity in vivo and expression in vitro. Proc Natl Acad Sci U S A (1986) 1.90
Molecular characterization of an attenuated human immunodeficiency virus type 2 isolate. J Virol (1990) 1.86
Coronary heart disease in the Western Collaborative Group Study. A follow-up experience of 4 and one-half years. J Chronic Dis (1970) 1.86
Multivariate prediction of coronary heart disease during 8.5 year follow-up in the Western Collaborative Group Study. Am J Cardiol (1976) 1.82
T-cell growth factor gene: lack of expression in human T-cell leukemia-lymphoma virus-infected cells. Science (1984) 1.82
Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest (1996) 1.82
Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis (1993) 1.76
Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis (1989) 1.76
The pathogenesis of a coronary thrombus. Am J Pathol (1966) 1.76
Posttraumatic stress disorder associated with peacekeeping duty in Somalia for U.S. military personnel. Am J Psychiatry (1997) 1.75
Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol (1998) 1.73
Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer (1981) 1.73
Clinical evaluation of halofantrine in acute malaria. J Assoc Physicians India (1993) 1.71
Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 1.70
Homology of genome of AIDS-associated virus with genomes of human T-cell leukemia viruses. Science (1984) 1.69
Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res (1999) 1.68
Characterization of a new primary human pancreatic tumor line. Cancer Invest (1986) 1.67
Splenic abscesses from 1987 to 1995. Am J Surg (1997) 1.67
Structure of simian immunodeficiency virus regulatory genes. Proc Natl Acad Sci U S A (1989) 1.65
Assessment of lung function using an air-flow meter. Lancet (1975) 1.65
Cushing's syndrome: adrenocortical hyperactivity secondary to neoplasms arising outside the pituitary-adrenal system. Q J Med (1966) 1.64
Preventability of malpractice claims in emergency medicine: a closed claims study. Ann Emerg Med (1990) 1.62
Brachial artery transection following closed elbow dislocation. J Trauma (1999) 1.62
Alteration of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients: summary results of the recurrent coronary prevention project. Am Heart J (1986) 1.60
Keratodermia Blennorrhagicum: Report of Case with Autopsy. Am J Pathol (1944) 1.60
Carcinoembryonic antigen (CEA) in patients with carcinoma of the digestive tract. Ann Surg (1972) 1.59
Pitfalls in the diagnosis of blunt diaphragmatic injury. Am J Surg (1995) 1.58
Esophageal tuberculosis: a rare presentation with hematemesis. Am J Gastroenterol (1991) 1.58
Neurogenic factors in pathogenesis of coronary heart disease. Med Clin North Am (1974) 1.57
The Giardia genome project database. FEMS Microbiol Lett (2000) 1.57
Experience with percutaneous dilational tracheostomy. Ann Otol Rhinol Laryngol (2000) 1.56
Development of an objective psychological test for the determination of the coronary-prone behavior pattern in employed men. J Chronic Dis (1967) 1.56
Relation of HTLV-4 to simian and human immunodeficiency-associated viruses. Nature (1987) 1.53
Modeling the epidemiology and economics of directly observed therapy in Baltimore. Int J Tuberc Lung Dis (2000) 1.52
Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II. Biomarker studies. Cancer (1985) 1.51
Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 1.51
Primary hypomagnesaemia with secondary hypocalcaemia in an infant. Lancet (1967) 1.49
Combined duodenal and colonic necrosis. An unusual sequela of caustic ingestion. J Clin Gastroenterol (1994) 1.49
Application of long-term collagenase disaggregation for the cytogenetic analysis of human solid tumors. Cancer Genet Cytogenet (1986) 1.49
Instantaneous and sudden deaths. Clinical and pathological differentiation in coronary artery disease. JAMA (1973) 1.48
Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer (1985) 1.48
Intussusception in adults. Mt Sinai J Med (2000) 1.47
Isopeptidase: a novel eukaryotic enzyme that cleaves isopeptide bonds. Proc Natl Acad Sci U S A (1982) 1.47
Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care (2001) 1.46
Aggression and counteraggression during child psychiatric hospitalization. J Am Acad Child Adolesc Psychiatry (1990) 1.45
Identification of human T cell leukemia/lymphoma virus type I antibodies, DNA, and protein in patients with polymyositis. Arthritis Rheum (1995) 1.44
Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation (2003) 1.43
Isolated congenital atresia of the left main coronary artery and atherosclerosis. Ann Thorac Surg (1993) 1.43
Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet (1984) 1.42
The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Free Radic Biol Med (1995) 1.39
Isolation and characterization of renin-expressing cell lines from transgenic mice containing a renin-promoter viral oncogene fusion construct. J Biol Chem (1990) 1.39
Clinical features of vivax malaria. Am J Trop Med Hyg (2001) 1.39
Trisomy 14: a new entity within acute nonlymphocytic leukemia. Cancer Genet Cytogenet (1989) 1.39
Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro (1982) 1.39
Histotoxicity of cyanoacrylate tissue adhesives. A comparative study. Arch Otolaryngol Head Neck Surg (1990) 1.39
Involvement of 6p in benign lipomas. A new cytogenetic entity? Cancer Genet Cytogenet (1989) 1.39
Concurrent chemoradiotherapy followed by surgery in locally advanced squamous cell carcinoma of the oesophagus: a single centre experience. Ann Acad Med Singapore (2005) 1.38